Exicure Inc XCUR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.72
- Day Range
- $1.58–1.98
- 52-Week Range
- $1.58–9.39
- Bid/Ask
- $1.66 / $1.76
- Shares Outstanding
- 6.37M
- Market Cap
- $10.84M
- Volume/Avg
- 3M / 224,999
Key Statistics
- Price/Earnings (Normalized)
- 2.23
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.exicuretx.com
Valuation
|
Metric
|
XCUR
|
|---|---|
Price/Earnings (Normalized) | 2.23 |
Price/Book Value | 5.23 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
XCUR
Financial Strength
|
Metric
|
XCUR
|
|---|---|
Quick Ratio | 0.60 |
Current Ratio | 0.79 |
Interest Coverage | — |
Quick Ratio
XCUR
Profitability
|
Metric
|
XCUR
|
|---|---|
Return on Assets (Normalized) | −51.10% |
Return on Equity (Normalized) | −125.43% |
Return on Invested Capital (Normalized) | −120.85% |
Return on Assets
XCUR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|R?&pD^# | LOCK|%YBBX | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|nnX>m# | LOCK|P?cp | $69B | |||
| argenx SE ADR
ARGX
| LOCK|CK$<<X& | LOCK|J! | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|YKK&Wf | LOCK|^>K< | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|cpw<F?C | LOCK|r> | $36B | |||
| Moderna Inc
MRNA
| LOCK|F<D#rD | LOCK|R? | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Q>g>l>< | LOCK|b#^v | $25B | |||
| Incyte Corp
INCY
| LOCK|q%DNrY | LOCK|%&R | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|X<!Wqb^ | LOCK|p?m | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|PD$&tFF | LOCK|^Hw | $16B |
United States